Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Condition: Squamous Cell Carcinoma of the Head and Neck Interventions: Drug: Monalizumab; Drug: Cetuximab Sponsors: AstraZeneca; Innate Pharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Erbitux | Head and Neck Cancer | Pharmaceuticals | Research